SEC For	rm 4 FORM	4	UNITED) ST/	ATES	SE	ECUR	ITI	ES AND	EX	СНА	NGE (сомм	ISSION					
						Washington, D.C. 20549										OMB APPROVAL			
Check this box if no longer subject to STATEMEN							CHAI	١G	es in Bi	SHIP	IP OMB Number: 3235-0287 Estimated average burden								
	tions may conti tion 1(b).	nue. <i>See</i>		Fil					a) of the Seci Investment (1934		hours	s per re	esponse:	0.5	
1. Name and Address of Reporting Person [*] Bronstein Ben						2. Issuer Name and Ticker or Trading Symbol Aldeyra Therapeutics, Inc. [ALDX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Mide						3. Date of Earliest Transaction (Month/Day/Year) 06/30/2023								Officer (give title below)			e Other (spe below)		
C/O ALDEYRA THERAPEUTICS, INC 131 HARTWELL AVENUE					4. lf	Line)								e)	ividual or Joint/Group Filing (Check Applicable				
(Street)					-									X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	LEXINGTON MA		02421		- Ru	Rule 10b5-1(c) Transaction Indication													
(City)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										that is intende	ed to					
		Tab	le I - Nor	n-Deriv	vative	Sec	curities	s Ac	quired, D	ispo	osed c	of, or Be	neficial	ly Owned	d				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date,			Transaction Disposed Of Code (Instr. 5)				ies Acquired (A) or Of (D) (Instr. 3, 4 and		Securities Fo Beneficially (D)		n: Direct	7. Nature of Indirect Beneficial Ownership	
								V Amount		(A) ((D)	Price	Transac	Reported Transaction(s) Instr. 3 and 4)			(Instr. 4)			
		Г							uired, Dis s, options					/ Owned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$8.39	06/30/2023			A		21,222		(1)	06/:	29/2033	Common Stock	21,222	\$0	21,22	2	D		
Stock Option (Right to Buy)	\$8.39	06/30/2023			A		1,372		(2)	06/:	29/2033	Common Stock	1,372	\$0	1,372	2	D		
Stock Option (Right to Buy)	\$8.39	06/30/2023			A		1,464		(3)	06/:	29/2033	Common Stock	1,464	\$0	1,464	4	D		

Explanation of Responses:

1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.

2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.

3. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.

/s/ Ben Bronstein

07/05/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.